Isoxsuprine hydrochloride in the horse: a review.
Authors: Erkert, Macallister
Journal: Journal of veterinary pharmacology and therapeutics
Summary
Isoxsuprine hydrochloride has long been promoted for managing navicular syndrome and laminitis in horses, primarily based on its vasodilatory properties and effects on blood rheology, but Erkert and Macallister's pharmacological review raises significant questions about its clinical efficacy. The drug operates as a mixed beta-adrenoreceptor antagonist and agonist, promoting vasodilation and reducing blood viscosity and platelet aggregation; however, its pharmacokinetic profile severely limits practical utility—intravenous administration produces a plasma half-life under 3 hours with rapid resolution of cardiovascular effects, whilst oral bioavailability is critically poor at just 2.2% due to substantial first-pass hepatic metabolism. Despite some clinical trial support for navicular disease treatment, the authors found that poor oral bioavailability, absent cardiovascular effects following oral dosing, and evolving understanding of navicular pathogenesis substantially undermine the evidence base for isoxsuprine use. For equine practitioners, this review suggests that reliance on oral isoxsuprine for navicular syndrome or laminitis is poorly justified by current pharmacological evidence, warranting reconsideration of treatment protocols and exploration of therapeutics with superior bioavailability and demonstrated mechanisms aligned with contemporary disease models.
Read the full abstract on PubMed
Practical Takeaways
- •Oral isoxsuprine is unlikely to be effective for navicular syndrome or laminitis in horses due to extremely poor bioavailability (2.2%) and lack of cardiovascular effects from oral dosing
- •If considering isoxsuprine, intravenous administration may theoretically provide benefits, but the short half-life (<3 hours) and questionable clinical evidence make it a poor first-line therapeutic choice
- •Current understanding of navicular syndrome pathogenesis has moved beyond the vasodilatory mechanism this drug targets; consider evidence-based alternatives with stronger clinical support
Key Findings
- •Isoxsuprine hydrochloride is a beta-adrenoreceptor antagonist with agonistic properties that promotes vasodilation and reduces blood viscosity and platelet aggregation
- •Intravenous isoxsuprine has a plasma half-life of less than 3 hours with rapid resolution of cardiovascular effects, but oral bioavailability is only 2.2% with high first-pass metabolism
- •Clinical trial evidence supports isoxsuprine use for navicular disease, but poor oral bioavailability and new understanding of navicular syndrome pathogenesis question its clinical utility
- •Isoxsuprine demonstrates apparent affinity for melanin, which may extend renal excretion and affect drug distribution